CHALLENGING CASES

Browse all CHALLENGING CASES
Challenging Cases: The Evolving Treatment Landscape for Therapy-Related and De Novo AML

CHALLENGING CASES

Challenging Cases: The Evolving Treatment Landscape for Therapy-Related and De Novo AML

Naval Daver, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Challenging Cases: Diagnosis and Treatment of Anemia or Iron Overload

CHALLENGING CASES

Challenging Cases: Diagnosis and Treatment of Anemia or Iron Overload

Marina Beltrami-Moreira, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Selecting Treatments for Cases in Relapsed or Refractory RCC

CHALLENGING CASES

Selecting Treatments for Cases in Relapsed or Refractory RCC

David Braun, MD, PhD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Thrombocytopenia Management: Practical Lessons For Clinicians

CHALLENGING CASES

Thrombocytopenia Management: Practical Lessons For Clinicians

Ronak Mistry, DO, Rahul Gosain, MD, MBA, Rohit Gosain, MD

NEW APPROVALS

Browse all NEW APPROVALS
Teclistamab Plus Daratumumab Approved for Relapsed or Refractory Multiple Myeloma After MajesTEC-3

NEW APPROVALS

Teclistamab Plus Daratumumab Approved for Relapsed or Refractory Multiple Myeloma After MajesTEC-3

Luciano Costa, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Transformative Data in Cisplatin-Ineligible MIBC: Clinical Implications of Enfortumab Vedotin Plus Pembrolizumab

NEW APPROVALS

Transformative Data in Cisplatin-Ineligible MIBC: Clinical Implications of Enfortumab Vedotin Plus Pembrolizumab

Thomas Powles, MD, MBBS, MRCP, Rahul Gosain, MD, MBA, Rohit Gosain, MD

The Promise of Anktiva: Expert Insight on IL-15 Therapy in Cancer Care

NEW APPROVALS

The Promise of Anktiva: Expert Insight on IL-15 Therapy in Cancer Care

Patrick Soon-Shiong, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

AQUILA Trial Insights: Daratumumab for the Treatment of High-Risk Smoldering Myeloma

NEW APPROVALS

AQUILA Trial Insights: Daratumumab for the Treatment of High-Risk Smoldering Myeloma

S. Vincent Rajkumar, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

TOX CHECK

Browse all TOX CHECK
PI3K/AKT Inhibitor Side Effect Management in Metastatic Breast Cancer

TOX CHECK

PI3K/AKT Inhibitor Side Effect Management in Metastatic Breast Cancer

Emily Gallagher, MD, PhD, Neil Iyengar, MD, Rohit Gosain, MD, Rahul Gosain, MD, MBA

Key Adverse Effects of Novel Antibody-Drug Conjugates in NSCLC

TOX CHECK

Key Adverse Effects of Novel Antibody-Drug Conjugates in NSCLC

Jacob Sands, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Optimizing ROS1 Inhibitor Therapy in NSCLC

TOX CHECK

Optimizing ROS1 Inhibitor Therapy in NSCLC

Estelamari Rodriguez, MD, MPH, Rohit Gosain, MD, Rahul Gosain, MD, MBA

How to Manage Side Effects of Tyrosine Kinase Inhibitors in CML

TOX CHECK

How to Manage Side Effects of Tyrosine Kinase Inhibitors in CML

Fadi Haddad, MD, Onyee Chan, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

TREATMENT ALGORITHMS

Browse all TREATMENT ALGORITHMS
Treatment Algorithm: The Shifting Landscape of HER2-Positive Breast Cancer

TREATMENT ALGORITHMS

Treatment Algorithm: The Shifting Landscape of HER2-Positive Breast Cancer

Virginia Kaklamani, MD, DSc, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Standard of Care Treatments for HR+ Metastatic Breast Cancer

TREATMENT ALGORITHMS

Standard of Care Treatments for HR+ Metastatic Breast Cancer

Kevin Kalinsky, MD, MS, FASCO, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Evolving Treatment Algorithms for Early-Stage Hormone Receptor–Positive Breast Cancer 

TREATMENT ALGORITHMS

Evolving Treatment Algorithms for Early-Stage Hormone Receptor–Positive Breast Cancer 

Erica Mayer, MD, MPH, Rahul Gosain, MD, MBA, Rohit Gosain, MD

The Current Treatment Pathways for Head and Neck Cancers

TREATMENT ALGORITHMS

The Current Treatment Pathways for Head and Neck Cancers

Fangdi Sun, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD